News | October 16, 2009

Correlagen Expands Cardiac Genetic Testing Services

October 16, 2009 – Correlagen recently expanded its CardioGeneScan test, the first comprehensive genetic test for the diagnosis of familial cardiac disease.

The CardioGeneScan tests for disease-causing variation in all genes known to be associated with familial cardiovascular diseases, including, cardiomyopathy, arrhythmia, thoracic aortic aneurysm, Noonan Syndrome and related diseases, and early-onset coronary artery disease. Due to its unprecedented breadth of testing, the CardioGeneScan has clinical utility for a wide range of patients with a family history of cardiac disease. Physicians will be able to assess the cardiac genetic make-up of their patients through a single test at a price that is affordable to their patients. More focused disease or gene-specific testing is also available.

“Identifying the genetic cause underlying cardiac disease in an affected family can benefit generations of family members,” said David Margulies, M.D., chairman and CEO of Correlagen. “Testing for the presence of familial disease variants can determine risk in young family members and help prevent sudden cardiac death through timely intervention. Early diagnosis can, for certain cardiac conditions, allow for early pharmacologic treatment, which can prevent severe disease and costly, painful interventions later. The CardioGeneScan test has a higher sensitivity than any other conventional genetic tests, since it looks for variation in more than one hundred relevant genes.”

The breadth of the CardioGeneScan is enabled through use of next-generation sequencing technology, which provides greater sequencing capacity at a lower per-gene cost than previous methods. As associations with inherited cardiac disease are demonstrated by researchers and clinicians in the field, Correlagen will add new genes to the CardioGeneScan to keep testing current.

In addition, physicians will receive Correlagen’s signature evergreen results report, which are revised periodically as new knowledge becomes available about the genetics of cardiac disease that impacts the clinical interpretation of previously identified variants. Such systematic report updating is enabled through Correlagen’s unique, evidence-based variant scoring protocols and result reporting processes.

For more information: www.correlagen.com

Related Content

World Heart Federation Launches Global Roadmap on Cardiovascular Disease Prevention Among Diabetics
News | Cardiac Diagnostics | September 04, 2019
At the European Society of Cardiology (ESC) Congress 2019 together with the World Congress of Cardiology, the World...
Insomnia Tied to Higher Risk of Heart Disease and Stroke

Image courtesy of the American Heart Association

News | Cardiac Diagnostics | August 19, 2019
People suffering from insomnia may have an increased risk of coronary artery disease, heart failure and stroke,...
Evolutionary Gene Loss May Help Explain Human Predisposition to Heart Attacks
News | Cardiac Diagnostics | July 29, 2019
The loss of a single gene two to three million years ago in our ancestors may have resulted in a heightened risk of...
U.S. Soldiers Have Worse Heart Health Than Civilians
News | Cardiac Diagnostics | June 06, 2019
Active duty Army personnel have worse cardiovascular health compared to people of similar ages in the civilian...
Late Dinner and No Breakfast Worsens Outcomes After Heart Attack
News | Cardiac Diagnostics | May 23, 2019
People who skip breakfast and eat dinner near bedtime have worse outcomes after a heart attack, according to research...
HRS Releases New Expert Consensus Statement on Arrhythmogenic Cardiomyopathy
News | Cardiac Diagnostics | May 14, 2019
The Heart Rhythm Society (HRS) released a first-of-its-kind consensus statement with guidance on the evaluation and...
New Best Practices Help Manage Heart Attack Patients Without Significant Signs
News | Cardiac Diagnostics | April 15, 2019
For the first time in the United States, doctors with the American Heart Association (AHA) have outlined best practices...
The most recent U.S. Food and Drug Administration (FDA) clearance was Siemens Healthineers high-sensitivity troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers. The test helps in the early diagnosis of myocardial infarctions without the need for serial tropic testing. The time to first results is 10 minutes.

The most recent U.S. Food and Drug Administration (FDA) clearance was Siemens Healthineers high-sensitivity troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers. The test helps in the early diagnosis of myocardial infarctions without the need for serial tropic testing. The time to first results is 10 minutes. 

Feature | Cardiac Diagnostics | March 22, 2019 | Linda C. Rogers, Ph.D.
Troponins are a family of proteins found in skeletal and heart (cardiac) muscle fibers that produce muscular contract
ACC/AHA Update Guidance for Preventing Heart Disease; Stroke
Feature | Cardiac Diagnostics | March 18, 2019
The choices we make every day can have a lasting effect on our heart and vascular health. Adopting a heart healthy...
Overlay Init